Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
MALMÖ, SE / ACCESS Newswire / September 10, 2026 / Ascelia Pharma (STO:ACE) completed the previously scheduled Type A
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
MALMÖ, SE / ACCESS Newswire / September 10, 2026 / Ascelia Pharma (STO:ACE) completed the previously scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) on September 9, 2026, regarding the Complete Response Letter (CRL) for the Orviglance® New Drug Application (NDA).
The meeting provided an opportunity to discuss the issues raised by the FDA in the CRL and to gain further clarity regarding obtaining regulatory approval for Orviglance in the US. Ascelia will provide an update on the regulatory path forward after receiving the FDA’s official meeting minutes. The minutes are expected within approximately 30 days.
Contact
Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: +46 735 179 118
About us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker:ACE). For more information, please visit http://www.ascelia.com.
Attachments
Ascelia Pharma completes FDA Type A meeting on Orviglance NDA
SOURCE: Ascelia Pharma
View the original press release on ACCESS Newswire
Media gallery
